65 related articles for article (PubMed ID: 30261006)
1. Designing antibodies against LRRK2-targeted tau epitopes.
Hamm M; Ladd TB; Levites Y; Golde TE; Giasson BI; Lewis J
PLoS One; 2018; 13(9):e0204367. PubMed ID: 30261006
[TBL] [Abstract][Full Text] [Related]
2. Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis.
Selenica ML; Davtyan H; Housley SB; Blair LJ; Gillies A; Nordhues BA; Zhang B; Liu J; Gestwicki JE; Lee DC; Gordon MN; Morgan D; Dickey CA
J Neuroinflammation; 2014 Sep; 11():152. PubMed ID: 25183004
[TBL] [Abstract][Full Text] [Related]
3. Western Blot of Tau Protein from Mouse Brains Extracts: How to Avoid Signal Artifacts.
Fereydouni-Forouzandeh P; Canet G; Diego-Diàz S; Rocaboy E; Petry S; Whittington RA; Planel E
Methods Mol Biol; 2024; 2754():309-321. PubMed ID: 38512673
[TBL] [Abstract][Full Text] [Related]
4. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain.
Boutajangout A; Ingadottir J; Davies P; Sigurdsson EM
J Neurochem; 2011 Aug; 118(4):658-67. PubMed ID: 21644996
[TBL] [Abstract][Full Text] [Related]
5. Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice.
Vitale F; Giliberto L; Ruiz S; Steslow K; Marambaud P; d'Abramo C
Acta Neuropathol Commun; 2018 Aug; 6(1):82. PubMed ID: 30134961
[TBL] [Abstract][Full Text] [Related]
6. [Human tau N-terminal domain-specific monoclonal antibodies: screening and application in blood detection].
Yan Z; Zhang Y; Jiang J; Liu Z; Wang H; Zhang Y; He J; Hong T
Sheng Wu Gong Cheng Xue Bao; 2024 May; 40(5):1571-1583. PubMed ID: 38783817
[TBL] [Abstract][Full Text] [Related]
7. Novel monoclonal antibodies targeting the microtubule-binding domain of human tau.
Croft CL; Moore BD; Ran Y; Chakrabarty P; Levites Y; Golde TE; Giasson BI
PLoS One; 2018; 13(4):e0195211. PubMed ID: 29608591
[TBL] [Abstract][Full Text] [Related]
8. Preclinical characterization and IND-enabling safety studies for PNT001, an antibody that recognizes cis-pT231 tau.
Foster K; Manca M; McClure K; Koivula P; Trojanowski JQ; Havas D; Chancellor S; Goldstein L; Brunden KR; Kraus A; Ahlijanian MK
Alzheimers Dement; 2023 Oct; 19(10):4662-4674. PubMed ID: 37002928
[TBL] [Abstract][Full Text] [Related]
9. Identification of high-performing antibodies for the reliable detection of Tau proteoforms by Western blotting and immunohistochemistry.
Ellis MJ; Lekka C; Holden KL; Tulmin H; Seedat F; O'Brien DP; Dhayal S; Zeissler ML; Knudsen JG; Kessler BM; Morgan NG; Todd JA; Richardson SJ; Stefana MI
Acta Neuropathol; 2024 May; 147(1):87. PubMed ID: 38761203
[TBL] [Abstract][Full Text] [Related]
10. Effects of Neighboring Phosphorylation Events on the Affinities of pT181-Tau Antibodies.
Min S; Mohallem R; Aryal UK; Kinzer-Ursem TL; Rochet JC
Anal Chem; 2023 Dec; 95(49):18241-18248. PubMed ID: 38014879
[TBL] [Abstract][Full Text] [Related]
11. Single domain antibodies targeting pathological tau protein: Influence of four IgG subclasses on efficacy and toxicity.
Congdon EE; Pan R; Jiang Y; Sandusky-Beltran LA; Dodge A; Lin Y; Liu M; Kuo MH; Kong XP; Sigurdsson EM
EBioMedicine; 2022 Oct; 84():104249. PubMed ID: 36099813
[TBL] [Abstract][Full Text] [Related]
12. Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative Phenotypes.
Goodwin MS; Sinyavskaya O; Burg F; O'Neal V; Ceballos-Diaz C; Cruz PE; Lewis J; Giasson BI; Davies P; Golde TE; Levites Y
Mol Ther; 2021 Feb; 29(2):859-872. PubMed ID: 33128896
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of LRRK2 following traumatic brain injury does not directly phosphorylate Thr
Donison N; Hintermayer M; Subramaniam M; Santandrea E; Volkening K; Strong MJ
Front Cell Neurosci; 2023; 17():1272899. PubMed ID: 38026695
[TBL] [Abstract][Full Text] [Related]
14. Yeast biopanning against site-specific phosphorylations in tau.
Arbaciauskaite M; Pirhanov A; Ammermann E; Lei Y; Cho YK
Protein Eng Des Sel; 2023 Jan; 36():. PubMed ID: 37294629
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of the human tau PHF core domain VQIINK complexed with the Fab domain of monoclonal antibody Tau2r3.
Tsuchida T; Susa K; Kibiki T; Tsuchiya T; Miyamoto K; In Y; Minoura K; Taniguchi T; Ishida T; Tomoo K
FEBS Lett; 2020 Apr; ():. PubMed ID: 32282060
[TBL] [Abstract][Full Text] [Related]
16. The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease.
Cresto N; Gardier C; Gubinelli F; Gaillard MC; Liot G; West AB; Brouillet E
Eur J Neurosci; 2019 Feb; 49(3):339-363. PubMed ID: 30269383
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic and Structural Origins of the Asymmetric Barrier to Prion-like Cross-Seeding between Tau-3R and Tau-4R.
Kumar H; Udgaonkar JB
J Mol Biol; 2018 Dec; 430(24):5304-5312. PubMed ID: 30267747
[TBL] [Abstract][Full Text] [Related]
18. Structural Basis for Recognition of a Unique Epitope by a Human Anti-tau Antibody.
Zhang H; Zhu X; Pascual G; Wadia JS; Keogh E; Hoozemans JJ; Siregar B; Inganäs H; Stoop EJM; Goudsmit J; Apetri A; Koudstaal W; Wilson IA
Structure; 2018 Dec; 26(12):1626-1634.e4. PubMed ID: 30318466
[TBL] [Abstract][Full Text] [Related]
19. Role of Rab GTPases in Alzheimer's Disease.
Zhang X; Huang TY; Yancey J; Luo H; Zhang YW
ACS Chem Neurosci; 2019 Feb; 10(2):828-838. PubMed ID: 30261139
[TBL] [Abstract][Full Text] [Related]
20. Differences in Stability, Activity and Mutation Effects Between Human and Mouse Leucine-Rich Repeat Kinase 2.
Langston RG; Rudenko IN; Kumaran R; Hauser DN; Kaganovich A; Ponce LB; Mamais A; Ndukwe K; Dillman AA; Al-Saif AM; Beilina A; Cookson MR
Neurochem Res; 2019 Jun; 44(6):1446-1459. PubMed ID: 30291536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
